Cargando…

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis

BACKGROUND: Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagpal, Aadya, Redvers, Richard P., Ling, Xiawei, Ayton, Scott, Fuentes, Miriam, Tavancheh, Elnaz, Diala, Irmina, Lalani, Alshad, Loi, Sherene, David, Steven, Anderson, Robin L., Smith, Yvonne, Merino, Delphine, Denoyer, Delphine, Pouliot, Normand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693253/ https://www.ncbi.nlm.nih.gov/pubmed/31409375 http://dx.doi.org/10.1186/s13058-019-1177-1

Ejemplares similares

The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
por: Lysyy, Taras, et al.
Publicado: (2019)

Integrin αvβ3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer
por: Nagpal, Aadya, et al.
Publicado: (2023)

Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
por: Kim, Soo-Hyun, et al.
Publicado: (2018)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo
por: Martin, Ana Carolina B.M., et al.
Publicado: (2017)

Bifunctional Aptamer–Doxorubicin Conjugate Crosses the Blood–Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells
por: Macdonald, Joanna, et al.
Publicado: (2020)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Optimization of a syngeneic murine model of bone metastasis
por: Farhoodi, Henry P., et al.
Publicado: (2020)

Neratinib for breast cancer
Publicado: (2019)

Laminin-511: A multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis
por: Pouliot, Normand, et al.
Publicado: (2013)

Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours.
por: Eccles, S. A., et al.
Publicado: (1980)

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis
por: Ellis, Leigh, et al.
Publicado: (2014)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

A syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis
por: Greenlee, Joshua D, et al.
Publicado: (2022)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host
por: Simons, Brian W., et al.
Publicado: (2019)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Neratinib protects pancreatic beta cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
por: Chia, Stephen K. L., et al.
Publicado: (2019)

Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model
por: Lin, Kai-Ti, et al.
Publicado: (2017)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

The natural history of metastasis of syngeneic murine squamous carcinoma and the prognostic implications of primary tumour size and duration of growth.
por: Peters, L. J.
Publicado: (1975)

Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model
por: Pessina, Augusto, et al.
Publicado: (2015)

Multimodality cellular and molecular imaging of concomitant tumour enhancement in a syngeneic mouse model of breast cancer metastasis
por: Parkins, Katie M., et al.
Publicado: (2018)

MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis
por: Ghosh, Arnab, et al.
Publicado: (2018)

Cyclophosphamide‐dependent Lymph Node Modification in Lymph Node Metastasis of MM48 Tumor Cells in Syngeneic Mice
por: Yoshida, Kikuyoshi, et al.
Publicado: (1990)

Development and characterization of mammary intraductal (MIND) spontaneous metastasis models for triple-negative breast cancer in syngeneic mice
por: Luo, Xu-Liang, et al.
Publicado: (2020)

Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain
por: Kijewska, Magdalena, et al.
Publicado: (2019)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vml2j7u65s931q0oqlr4hbpf68